Skip to main content
. 2022 Jan 31;32(1):29–39. doi: 10.1089/nat.2021.0043

Table 3.

Study Drug-Related Treatment-Emergent Adverse Events in Combined Parts 1 and 2

AEs, n (%) Total golodirsen group (n = 25)
Any TEAE related to study drug 9 (36.0)
 Pyrexia 3 (12.0)
 Headache 2 (8.0)
 Proteinuria 2 (8.0)
 Syncope 1 (4.0)
 Erythema 1 (4.0)
 Rash 1 (4.0)
 Skin exfoliation 1 (4.0)
 Sinus tachycardia 1 (4.0)
 Tachycardia 1 (4.0)
 Gastroenteritis 1 (4.0)
 Blood pressure decreased 1 (4.0)
 Hyperglycemia 1 (4.0)

TEAE, treatment-emergent adverse event.